A newly published paper in the Journal of Clinical Oncology has confirmed — based on a prospective study (as opposed to retrospective data) — that there is a strong risk association between a germline mutation of the BRCA2 gene and risk for metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: BRCA2, germline, mutation, screening | 1 Comment »
Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, ARCHES, deprivation, enzalutamide, hormone, outcome, sensitive, standard, trial | 2 Comments »
A paper in the journal Oncotarget has suggested that patients who have progressed on treatment with enzalutamide (Xtandi) may be good candidates for treatment with one of the checkpoint inhibitors like pembrolizumab (Keytruda), nivolumab (Opdivo), or even ipilimumab (Yervoy). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, checkpoiny, CRPC, enzalutamide, inhibitor, resistant | Leave a comment »
Some 3 years ago we first commented on a Phase II trial of a drug now called topsalycin (but then known as PRX302) in the treatment of low- to intermediate-risk, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Leave a comment »
